Knowledge, attitudes and practices during a community-level ivermectin distribution campaign in Guatemala.
Community acceptance and participation are essential for the success of mass ivermectin chemotherapy programmes for onchocerciasis (river blindness). To explore the local understanding of the purpose of ivermectin and willingness to continue taking the drug, we performed questionnaire surveys in four communities with hyperendemic onchocerciasis after each of three ivermectin treatment rounds. More than 100 respondents participated in each KAP survey, representing the heads of 30% of the households in each community. The respondents rarely stated that the goal of the ivermectin treatment programme was to prevent visual loss. Instead, they said they were taking the drug for their general well-being, to cure the onchocercal nodule (filaria), or to cure the microfilaria, a term newly introduced by agents of the treatment programme. The principal reason identified for refusal to take ivermectin was anxiety about drug-related adverse reactions, and there were marked differences between communities in acceptance of treatment. In one community over 50% of residents initially refused to take ivermectin, although participation rates improved somewhat after programmatic adjustments. We recommend that ivermectin distribution programmes establish surveillance activities to detect where acceptance is poor, so that timely and community-specific adjustments may be devised to improve participation.
Richards
F O
FO
Centers for Disease Control and Prevention, Atlanta, GA 30341, USA.
Klein
R E
RE
Gonzáles-Peralta
C
C
Flores
R Z
RZ
Roman
S G
SG
Ramírez
J C
JC
Flores
G Z
GZ
D018672:Community Health Planning / Q000458:organization & administration; D003906:Developing Countries; D005260:Female; D006166:Guatemala; D006266:Health Education / Q000458:organization & administration* / Q000706:statistics & numerical data; D007722:Health Knowledge, Attitudes, Practice; D006302:Health Services Research; D006801:Humans; D007197:Indians, Central American; D007559:Ivermectin / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009855:Onchocerciasis / Q000188:drug therapy* / Q000517:prevention & control; D010358:Patient Participation / Q000706:statistics & numerical data; D011322:Primary Prevention / Q000458:organization & administration*; D011795:Surveys and Questionnaires